Literature DB >> 30711999

Combination of Serum Albumin and Cholinesterase Levels as Prognostic Indicator in Patients ith Colorectal Cancer.

Manabu Yamamoto1, Hiroaki Saito2, Chihiro Uejima1, Akimitsu Tanio1, Yoichiro Tada1, Tomoyuki Matsunaga1, Teruhisa Sakamoto1, Soichiro Honjo1, Keigo Ashida1, Yoshiyuki Fujiwara1.   

Abstract

BACKGROUND/AIM: Nutritional status is strongly associated with cancer prognosis. The aim of this study was to identify the most useful combination of nutrition-related serum markers for predicting prognosis of patients with colorectal cancer (CRC). PATIENTS AND METHODS: A total of 523 patients who underwent proctocolectomies for CRC at our hospital were enrolled in this study. Serum concentrations of albumin, cholinesterase and total cholesterol, and total peripheral lymphocyte count (TLC) were used as nutrition-related markers.
RESULTS: In multivariate analysis of nutrition-related markers, serum albumin and cholinesterase levels were found to be independent prognostic indicators. Cut-off values from receiver operating characteristic analyses were used to sort patients as ChEHigh or ChELow (serum cholinesterase level ≥ or <221.5), and as AlbHigh or AlbLow (serum albumin level ≥ or <3.85). We then sorted them into three groups: ChEHigh/AlbHigh (Group A); ChEHigh/AlbLow or ChELow/AlbHigh (Group B); and ChELow/AlbLow (Group C). Their 5-year overall survival rates differed significantly (Group A: 81.6%, Group B: 62.1%, Group C: 42.7%, p<0.0001); as did their 5-year disease-specific survival rates (Group A: 90.1%, Group B: 73.8%, Group C: 62.2%, p<0.0001).
CONCLUSION: The combination of serum cholinesterase and albumin levels is useful for predicting the prognosis of patients with CRC. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Albumin; biomarker; cholinesterase; colorectal cancer; prognosis

Mesh:

Substances:

Year:  2019        PMID: 30711999     DOI: 10.21873/anticanres.13217

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Predicting Overall Survival Using Preoperative Nutritional and Inflammation Status for Colorectal Cancer.

Authors:  Tamuro Hayama; Tsuyoshi Ozawa; Mitsuo Tsukamoto; Yoshihisa Fukushima; Ryu Shimada; Keijiro Nozawa; Keiji Matsuda; Shoichi Fujii; Takeo Fukagawa; Yojiro Hashiguchi
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  Advanced Age Is a Risk Factor for Recurrence After Resection in Stage II Colorectal Cancer.

Authors:  Kosuke Mima; Junji Kurashige; Nobutomo Miyanari; Atsushi Morito; Shinsei Yumoto; Takashi Matsumoto; Keisuke Kosumi; Mitsuhiro Inoue; Takao Mizumoto; Tatsuo Kubota; Hideo Baba
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

3.  Combination of C-reactive Protein and Monocyte Count Is a Useful Prognostic Indicator for Patients With Colorectal Cancer.

Authors:  Manabu Yamamoto; Hiroaki Saito; Kazushi Hara; Ken Sugezawa; Chihiro Uejima; Akimitsu Tanio; Yoichiro Tada; Kyoichi Kihara; Teruhisa Sakamoto; Soichiro Honjo; Yoshiyuki Fujiwara
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

4.  Prognostic significance of FA score based on plasma fibrinogen and serum albumin in patients with epithelial ovarian cancer.

Authors:  Yuan Li; Jia-Ni Yang; Shan-Shan Cheng; Yu Wang
Journal:  Cancer Manag Res       Date:  2019-08-14       Impact factor: 3.989

5.  Prognostic Value of the Combination of CEA and Fibrinogen/Albumin Ratio in Resectable Gastric Cancer.

Authors:  Junbin Zhang; Jiayin Ruan; Weibin Wang; Yimin Lu; Haiyong Wang; Xiongfei Yu; Haohao Wang; Lisong Teng
Journal:  Cancer Manag Res       Date:  2020-04-23       Impact factor: 3.989

6.  The Prognostic Value of New Index (LANR) Composed of Pre-operative Lymphocytes, Albumin, and Neutrophils in Patients With Resectable Colorectal Cancer.

Authors:  Xinjun Liang; Shuang Yao; Ping Lu; Yifei Ma; Hongli Xu; Zhucheng Yin; Junjie Hu; Yanyan Liu; Shaozhong Wei
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

7.  Serum Cholinesterases, a Novel Marker of Clinical Activity in Inflammatory Bowel Disease: A Retrospective Case-Control Study.

Authors:  Xiaona Shao; Lei Yang; Keyue Hu; Ruiwei Shen; Qunqun Ye; Xiaogang Yuan; Qiang Zhao; Jianwei Shen
Journal:  Mediators Inflamm       Date:  2020-07-14       Impact factor: 4.711

8.  Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma.

Authors:  Chen Zheng; Shuaibin Liu; Jiexiong Feng; Xiang Zhao
Journal:  Cancer Manag Res       Date:  2020-04-01       Impact factor: 3.989

9.  Serum cholinesterase may independently predict prognosis in non-small-cell lung cancer.

Authors:  Hailiang Ran; Jie Ma; Le Cai; Hai Zhou; Zhongqin Yuan; Ying Chen; Wei Chang; Yunchao Huang; Yuanyuan Xiao
Journal:  BMC Cancer       Date:  2022-01-21       Impact factor: 4.430

10.  Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients.

Authors:  Eva Valentina Klocker; Dominik Andreas Barth; Jakob Michael Riedl; Felix Prinz; Joanna Szkandera; Konstantin Schlick; Peter Kornprat; Karoline Lackner; Jörg Lindenmann; Herbert Stöger; Michael Stotz; Armin Gerger; Martin Pichler
Journal:  Cancers (Basel)       Date:  2020-05-04       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.